{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T15:13:34Z","timestamp":1793978014768,"version":"4.8.0"},"reference-count":53,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2024,10,1]]},"abstract":"Importance<\/jats:title>Immune checkpoint inhibitors (ICIs) improve outcomes in a wide range of cancers; however, serious adverse effects, including cardiovascular adverse effects (CVAEs), can occur.<\/jats:p><\/jats:sec>Objective<\/jats:title>To determine the incidence of CVAEs and analyze data on the management of myocarditis in patients exposed to ICIs.<\/jats:p><\/jats:sec>Data Sources<\/jats:title>PubMed, Embase, and Cochrane Central Register of Controlled Trials from inception were searched on April 4, 2023.<\/jats:p><\/jats:sec>Study Selection<\/jats:title>Two separate studies were performed. Key inclusion criteria for study 1 were phases 1 to 4 trials involving adults with malignant neoplasms treated with an ICI and toxicity data; for study 2, publications (case reports and retrospective analyses) on clinical manifestations and treatment of patients with ICI-induced CVAEs. Studies with dose escalation or fewer than 11 patients in each group and all case reports, retrospective analyses, letters, reviews, and editorials were excluded from study 1. Studies not published in English were excluded from study 2.<\/jats:p><\/jats:sec>Data Extraction and Synthesis<\/jats:title>The PRISMA guidelines and Cochrane Handbook for Systematic Reviews were followed. Data were extracted independently by 2 researchers. A meta-analysis of the incidence of CVAEs in clinical trials and a systematic review of the evidence for the management of myocarditis were performed. Data were pooled using a random-effects model.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>In study 1, the primary outcome was incidence CVAEs in clinical trials with ICIs and ICI combination therapies. Study 2 examined evidence supporting specific management strategies that may decrease the mortality rate of myocarditis. The primary outcomes were planned before data collection began.<\/jats:p><\/jats:sec>Results<\/jats:title>In study 1, a total of 83 315 unique participants in 589 unique trials were included in the meta-analysis. Incidence of CVAEs induced by anti\u2013programmed cell death 1 and\/or programmed cell death ligand 1 was 0.80% (95% CI, 0%-1.66%) in clinical trials, with no differences between the compounds, except for cemiplimab, which was associated with a higher risk of CVAEs. Incidence of CVAEs following ipilimumab treatment was 1.07% (95% CI, 0%-2.58%). The incidence of myocarditis was significantly higher following treatment with dual ICIs. However, CVAE incidence was not higher with dual ICIs, ICI combination with chemotherapy, or tyrosine kinase inhibitors. Evidence from randomized clinical trials on recommended monitoring and treatment strategies for ICI-induced myocarditis was lacking. Study 2 showed that myocarditis-associated mortality occurred in 83 of 220 patients (37.7%). Prospective data from 40 patients with myocarditis indicated that systematic screening for respiratory muscle involvement, coupled with active ventilation, prompt use of abatacept, and the addition of ruxolitinib, may decrease the mortality rate.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>Immune checkpoint inhibitor\u2013induced CVAEs and\/or myocarditis were recorded in 1.07% of patients in clinical trials. The CVAE mortality risk remains high, justifying the need for monitoring and management strategies for which evidence from randomized clinical trials is absent. Early recognition, ICI therapy cessation, prompt initiation of corticosteroid therapy, and escalation of therapy are all crucial elements for achieving optimal outcomes. Prospective clinical trials or at least prospective registration of treatments and outcomes are highly warranted.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamaoncol.2024.3065","type":"journal-article","created":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T17:54:10Z","timestamp":1724349250000},"page":"1390","source":"Crossref","is-referenced-by-count":134,"title":["Immune Checkpoint Inhibitor\u2013Induced Cardiotoxicity"],"prefix":"10.1001","volume":"10","author":[{"given":"Dorte Lisbet","family":"Nielsen","sequence":"first","affiliation":[{"name":"Department of Oncology, Herlev and Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten Bogh","family":"Juhl","sequence":"additional","affiliation":[{"name":"Department of Sports Science and Clinical Biomechanics, University of Southern Denmark, Odense, Denmark"},{"name":"Department of Physiotherapy and Occupational Therapy, Herlev and Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ole Haagen","family":"Nielsen","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Herlev and Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inna Markovna","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Oncology, Herlev and Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joerg","family":"Herrmann","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"6382","key":"coi240043r1","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade.","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"issue":"4","key":"coi240043r2","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/s41571-022-00600-w","article-title":"Immune-checkpoint inhibitors: long-term implications of toxicity.","volume":"19","author":"Johnson","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"coi240043r3","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade.","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"issue":"2","key":"coi240043r4","doi-asserted-by":"publisher","first-page":"91","DOI":"10.31662\/jmaj.2021-0001","article-title":"Mechanisms and management of immune checkpoint inhibitor-related cardiac adverse events.","volume":"4","author":"Kadowaki","year":"2021","journal-title":"JMA J"},{"issue":"1","key":"coi240043r5","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1159\/000498985","article-title":"Cardiac toxicity associated with immune checkpoint inhibitors: case series and review of the literature.","volume":"12","author":"Agrawal","year":"2019","journal-title":"Case Rep Oncol"},{"issue":"12","key":"coi240043r6","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis.","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"issue":"10124","key":"coi240043r7","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/S0140-6736(18)30533-6","article-title":"Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis.","volume":"391","author":"Moslehi","year":"2018","journal-title":"Lancet"},{"issue":"18","key":"coi240043r8","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade.","volume":"375","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"issue":"9","key":"coi240043r9","doi-asserted-by":"publisher","first-page":"e447","DOI":"10.1016\/S1470-2045(18)30457-1","article-title":"Immune checkpoint inhibitors and cardiovascular toxicity.","volume":"19","author":"Lyon","year":"2018","journal-title":"Lancet Oncol"},{"key":"coi240043r10","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.critrevonc.2019.04.008","article-title":"Efficacy and safety of combination immunotherapy for malignant solid tumors: a systematic review and meta-analysis.","volume":"138","author":"Wei","year":"2019","journal-title":"Crit Rev Oncol Hematol"},{"issue":"8","key":"coi240043r11","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/s41569-020-0348-1","article-title":"Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia.","volume":"17","author":"Herrmann","year":"2020","journal-title":"Nat Rev Cardiol"},{"issue":"3","key":"coi240043r13","doi-asserted-by":"publisher","DOI":"10.1002\/hsr2.178","article-title":"Arcsine-based transformations for meta-analysis of proportions: pros, cons, and alternatives.","volume":"3","author":"Lin","year":"2020","journal-title":"Health Sci Rep"},{"issue":"23","key":"coi240043r16","doi-asserted-by":"publisher","first-page":"6424","DOI":"10.1158\/1078-0432.CCR-21-2001","article-title":"Phase II study of pembrolizumab in combination with doxorubicin in metastatic and unresectable soft-tissue sarcoma.","volume":"27","author":"Livingston","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"1","key":"coi240043r17","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.115.002661","article-title":"Cancer therapy-related cardiac dysfunction and heart failure: part 1: definitions, pathophysiology, risk factors, and imaging.","volume":"9","author":"Bloom","year":"2016","journal-title":"Circ Heart Fail"},{"issue":"3","key":"coi240043r18","first-page":"66","article-title":"Cardiotoxicity of non-anthracycline cancer chemotherapy agents.","volume":"9","author":"Briasoulis","year":"2022","journal-title":"J Cardiovasc Dev Dis"},{"key":"coi240043r19","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41698-018-0056-z","article-title":"Cardiotoxicity with vascular endothelial growth factor inhibitor therapy.","volume":"2","author":"Touyz","year":"2018","journal-title":"NPJ Precis Oncol"},{"issue":"5","key":"coi240043r20","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1158\/2159-8290.CD-22-1180","article-title":"Abatacept\/ruxolitinib and screening for concomitant respiratory muscle failure to mitigate fatality of immune-checkpoint inhibitor myocarditis.","volume":"13","author":"Salem","year":"2023","journal-title":"Cancer Discov"},{"key":"coi240043r21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1006860","article-title":"Cardiotoxicity of immune checkpoint inhibitors: a frequency network meta-analysis.","volume":"13","author":"Liu","year":"2022","journal-title":"Front Immunol"},{"key":"coi240043r22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.908173","article-title":"Cardiovascular toxicity with PD-1\/PD-L1 inhibitors in cancer patients: a systematic review and meta-analysis.","volume":"13","author":"Liu","year":"2022","journal-title":"Front Immunol"},{"issue":"10","key":"coi240043r23","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1002\/ejhf.2289","article-title":"Cardiotoxicity associated with immune checkpoint inhibitor therapy: a meta-analysis.","volume":"23","author":"Rubio-Infante","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"coi240043r24","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.ejca.2021.01.043","article-title":"Cardiotoxicity of immune checkpoint inhibitors: a systematic review and meta-analysis of randomised clinical trials.","volume":"148","author":"Agostinetto","year":"2021","journal-title":"Eur J Cancer"},{"issue":"8","key":"coi240043r25","doi-asserted-by":"publisher","first-page":"725","DOI":"10.2217\/imt-2018-0118","article-title":"Cardiotoxicity with immune system targeting drugs: a meta-analysis of anti\u2013PD\/PD-L1 immunotherapy randomized clinical trials.","volume":"11","author":"Rahouma","year":"2019","journal-title":"Immunotherapy"},{"key":"coi240043r26","doi-asserted-by":"publisher","first-page":"S8","DOI":"10.21037\/tlcr.2017.12.10","article-title":"Evaluation of rare but severe immune related adverse effects in PD-1 and PD-L1 inhibitors in non\u2013small cell lung cancer: a meta-analysis.","volume":"6","author":"Hu","year":"2017","journal-title":"Transl Lung Cancer Res"},{"issue":"11","key":"coi240043r27","doi-asserted-by":"publisher","first-page":"584","DOI":"10.4330\/wjc.v12.i11.584","article-title":"Cardiac adverse events of immune checkpoint inhibitors in oncology patients: a systematic review and meta-analysis.","volume":"12","author":"Nso","year":"2020","journal-title":"World J Cardiol"},{"issue":"2","key":"coi240043r28","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1684\/ejd.2021.4009","article-title":"Cardiac adverse events associated with anti\u2013PD-1 therapy in patients treated for advanced melanoma: relevance of dosing troponin T levels.","volume":"31","author":"Scard","year":"2021","journal-title":"Eur J Dermatol"},{"issue":"1","key":"coi240043r29","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s00392-020-01648-3","article-title":"Re-introducing immunotherapy in patients surviving immune checkpoint inhibitors\u2013mediated myocarditis.","volume":"110","author":"Peleg Hasson","year":"2021","journal-title":"Clin Res Cardiol"},{"key":"coi240043r30","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.ejca.2016.02.024","article-title":"Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti\u2013PD-1 therapy.","volume":"60","author":"Zimmer","year":"2016","journal-title":"Eur J Cancer"},{"issue":"16","key":"coi240043r31","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors.","volume":"71","author":"Mahmood","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"coi240043r32","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.e15100","article-title":"Risk factors for myocarditis associated with immune checkpoint inhibitors using real-world clinical data.","volume":"38","author":"Jain","year":"2020","journal-title":"J Clin Oncol"},{"issue":"11","key":"coi240043r33","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1001\/jamaoncol.2019.3113","article-title":"Factors associated with immune checkpoint inhibitor\u2013related myocarditis.","volume":"5","author":"Zamami","year":"2019","journal-title":"JAMA Oncol"},{"issue":"12","key":"coi240043r34","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study.","volume":"19","author":"Salem","year":"2018","journal-title":"Lancet Oncol"},{"issue":"11","key":"coi240043r35","doi-asserted-by":"publisher","first-page":"3480","DOI":"10.3390\/cancers12113480","article-title":"Pre-existing cardiovascular conditions as clinical predictors of myocarditis reporting with immune checkpoint inhibitors: a VigiBase study.","volume":"12","author":"Noseda","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"11","key":"coi240043r36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0272022","article-title":"Immune checkpoint inhibitor monotherapy is associated with less cardiac toxicity than combination therapy.","volume":"17","author":"Cone","year":"2022","journal-title":"PLoS One"},{"issue":"6","key":"coi240043r37","doi-asserted-by":"publisher","first-page":"e69","DOI":"10.1161\/CIR.0000000000000745","article-title":"Recognition and initial management of fulminant myocarditis: a scientific statement from the American Heart Association.","volume":"141","author":"Kociol","year":"2020","journal-title":"Circulation"},{"issue":"18","key":"coi240043r38","doi-asserted-by":"publisher","first-page":"e876","DOI":"10.1161\/CIR.0000000000001062","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines.","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"issue":"11","key":"coi240043r39","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1080\/14737140.2021.1979396","article-title":"Immune checkpoint inhibitors and cardiotoxicity: possible mechanisms, manifestations, diagnosis and management.","volume":"21","author":"Eftekhar","year":"2021","journal-title":"Expert Rev Anticancer Ther"},{"issue":"41","key":"coi240043r40","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS).","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"issue":"36","key":"coi240043r41","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update.","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"issue":"3","key":"coi240043r42","doi-asserted-by":"publisher","first-page":"230","DOI":"10.6004\/jnccn.2020.0012","article-title":"NCCN Guidelines insights: Management of Immunotherapy-Related Toxicities, Version 1.2020.","volume":"18","author":"Thompson","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"issue":"6","key":"coi240043r43","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events.","volume":"9","author":"Brahmer","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"12","key":"coi240043r44","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann Oncol"},{"issue":"24","key":"coi240043r45","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1161\/CIRCULATIONAHA.119.044703","article-title":"Major adverse cardiovascular events and the timing and dose of corticosteroids in immune checkpoint inhibitor-associated myocarditis.","volume":"141","author":"Zhang","year":"2020","journal-title":"Circulation"},{"issue":"18","key":"coi240043r46","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1093\/eurheartj\/ehaa051","article-title":"Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis.","volume":"41","author":"Zhang","year":"2020","journal-title":"Eur Heart J"},{"issue":"4","key":"coi240043r47","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-004699","article-title":"Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of concept.","volume":"10","author":"Nguyen","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"1","key":"coi240043r48","doi-asserted-by":"publisher","DOI":"10.1093\/immadv\/ltac012","article-title":"Plasma exchange for severe immune-related adverse events from checkpoint inhibitors: an early window of opportunity?","volume":"2","author":"Katsumoto","year":"2022","journal-title":"Immunother Adv"},{"issue":"11","key":"coi240043r49","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1001\/jamacardio.2021.2241","article-title":"Clinical strategy for the diagnosis and treatment of immune checkpoint inhibitor-associated myocarditis: a narrative review.","volume":"6","author":"Lehmann","year":"2021","journal-title":"JAMA Cardiol"},{"issue":"3","key":"coi240043r50","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.cjco.2020.11.004","article-title":"Plasma exchange for immune checkpoint inhibitor\u2013induced myocarditis.","volume":"3","author":"Yogasundaram","year":"2020","journal-title":"CJC Open"},{"key":"coi240043r51","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102440","article-title":"Immune checkpoint inhibitor\u2013induced diarrhea and colitis: incidence and management: a systematic review and meta-analysis.","volume":"109","author":"Nielsen","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"coi240043r12","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2022"},{"key":"coi240043r14","volume-title":"National Institutes of Health Common Terminology Criteria for Adverse Events (CTCAE)","year":"2017"},{"key":"coi240043r15","volume-title":"Assessing Harms When Comparing Medical Interventions: Methods Guide for Effectiveness and Comparative Effectiveness Reviews","author":"Chou","year":"2008"},{"key":"coi240043r52","unstructured":"AbataCept for the Treatment of Immune-cHeckpoint Inhibitors Induced mYocarditiS (ACHLYS). ClinicalTrials.gov identifier NCT05195645. Updated April 30, 2024. Accessed November 10, 2023. https:\/\/clinicaltrials.gov\/study\/NCT05195645"},{"key":"coi240043r53","unstructured":"Abatacept in Immune Checkpoint Inhibitor Myocarditis (ATRIUM). ClinicalTrials.gov identifier NCT05335928. Updated September 7, 2023. Accessed November 10, 2023. https:\/\/clinicaltrials.gov\/study\/NCT05335928"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2822706\/jamaoncology_nielsen_2024_oi_240043_1728488924.55067.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T15:16:34Z","timestamp":1729178194000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2822706"}},"subtitle":["A Systematic Review and Meta-Analysis"],"short-title":[],"issued":{"date-parts":[[2024,10,1]]},"references-count":53,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2024.3065","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10,1]]}}}